Drug firm Granules India Ltd. on Monday said it has received approval from the U.S. health regulator to market a generic product to treat high blood pressure.
The company has received approval from the U.S. Food and Drug Administration to market Losartan Potassium tablets in strengths of 25 mg, 50 mg, and 100 mg, Granules India said in a regulatory filing.
The Hyderabad-based company's product is bioequivalent to the Organon LLC's Cozaar tablets.
ADVERTISEMENT
According to IQVIA/IMS Health, the current annual U.S. market for Losartan potassium tablets is around $336 million.
Shares of Granules India were trading 1.24% down at Rs 281.75 apiece on the BSE.
ADVERTISEMENT
RECOMMENDED FOR YOU
AU Small Finance Bank Shares Rise Over 7% After RBI's In-Principle Nod To Become Universal Bank
Aug 08, 2025
Manipal Hospitals Seeks CCI Nod To Acquire Sahyadri Hospitals For About Rs 6,400 Crore
Aug 03, 2025
ChrysCapital Seeks CCI Nod To Acquire Bakery Chain Theobroma
Jul 16, 2025
AstraZeneca Pharma Gets CDSCO Nod For Import, Sale Of Bladder Cancer Drug
Jul 14, 2025
POPULAR
1
Nepal-India Relations More Than Roti And Beti, Says Deputy PM Singh
2
Retirement Planning: What Does It Take To Make Rs 10 Crore Through Investments?
3
Earning Rs 4.5 Lakh A Month And Still Unhappy? CA Explains Reasons And Shares Money Management Tips
4
Rebuilding Momentum: Can Bata Find Its Footing Again?
5